Innovate UK



Antimicrobial Resistance (AMR)

Switzerland, 23 – 28 February 2025
Global Business Innovation Programme

Contents

Welcome

As part of our Global Business Innovation Programme (GBIP), Innovate UK are delighted to bring a delegation of some of the UK's leading Antimicrobial Resistance (AMR) businesses, building solutions with AMR at the core of their value proposition.

AMR is a globally escalating hidden pandemic causing serious human and social impact with the highest burdens in low-resource settings. It has been estimated that in 2019 some 4.95 million deaths were associated with bacterial AMR, including 1.27 million deaths attributable to bacterial AMR[1].

Antimicrobials are becoming more and more ineffective and infections more difficult to treat. This is also putting modern medicine at risk with cancer chemotherapy, stem cell therapy, caesarean sections and other surgeries dependent on antimicrobials to prevent infection. In addition, previously treatable illnesses such as pneumonia, tuberculosis, and even minor wound infections are becoming increasingly difficult to address.

This GBIP contributes to Innovate UK's ongoing commitment to tackle the AMR crisis by driving research, development and commercialisation of novel antimicrobials, preventives such as vaccines and AMR diagnostics in the UK's AMR industry through joint innovation and international collaboration with Switzerland.

Our delegation of 16 ambitious UK AMR companies will use the innovation visit to Switzerland as an opportunity to build business relations with key stakeholders from the global AMR industry, engage with other professionals and initiate forward-focused collaboration. The combination of commercial expertise, creative excellence and technological innovation across the UK and Switzerland will generate a significant value add for companies who operate in AMR markets and add to the global curbing of AMR.

We invite you to share insights, thought-provoking ideas and make new connections with the UK AMR companies that can open new business opportunities and result in further mutual growth and improved control of AMR. On behalf of the GBIP organisers, we would like to thank our gracious hosts, attendees, delegates and all our partner organisations for their invaluable contributions to this programme.

Thank you for your support.

Dr. Phil Packer
Innovation Lead
Innovate UK

Sophie Mifsud
Europe Partnership Manager
Innovate UK

Bita Najafi
Project Manager
Innovate UK Business Growth

Rocky Moore
Innovation & Growth Specialist
Innovate UK Business Growth

[1]Source: The Lancet (https://doi.org/10.1016/S0140-6736(21)02724-0)

Global Business Innovation Programmes

The Global Business Innovation Programmes, organised by Innovate UK, bring together cohorts of innovative UK businesses looking to grow and scale globally. Each programme focuses on a specific country, a technology or sector area, and enables the businesses to build global collaborations and partnerships to explore innovation opportunities.

Innovative UK businesses will tap into complementary knowledge, skills and facilities in the chosen country and develop understanding, cultural insight, and networks.

It will support businesses with a structured three-phase programme: get ready for the market, visit the market, and exploit the opportunity, together with harnessing the expertise of an Innovate UK innovation and growth specialist to maximise the opportunities and impact for the business.

This brochure details the businesses that are taking part in the AMR Global Business Innovation Programme with Switzerland and gives an overview of their business and objectives for this visit.

Antimicrobial Resistance within Switzerland and the UK

Switzerland and the UK have unique capabilities and technologies that can assist other nations to address AMR. There is a wide and deep expertise in this UK business delegation and the global AMR 'markets' offer significant opportunities to join forces and help bring forward the development of novel antimicrobial strategies, diagnostic tools, preventives and more.

The Swiss methodology to tackle AMR is a One Health approach, as described in their national Strategy (StAR – Strategy on Antibiotic Resistance). This highlights a deep understanding of, and commitment to the problems of AMR. The Swiss Life Sciences industry, particularly in the Basel region, is a world leader and the driving force of the Swiss economy, housing some 800 Life Sciences companies including the headquarters of major pharma firms such as Roche, Novartis and Sandoz.

The UK national action plan to tackle AMR sets out a 20-year vision to combat AMR through lowering the burden of infection and better treatment of resistant infections, development and optimal use of antimicrobials and good stewardship across all sectors. This is promoting access to safe and effective antimicrobials and the implementation of new diagnostics, vaccines and interventions. The UK boasts a strong research base, a thriving innovation climate and a large number of groundbreaking companies focused on developing new antibiotics, AMR diagnostics and preventives such as vaccines.

Innovate UK and Innovate UK Business Growth

Innovate UK

Innovate UK, part of UK Research and Innovation, is the UK's innovation agency. It works to create a better future by inspiring, involving and investing in businesses developing life-changing innovations. Its mission is to help companies to grow through their development and commercialisation of new products, processes and services, supported by an outstanding innovation ecosystem that is agile, inclusive and easy to navigate.

Contact

Phone: **+44 (0)1793 361 000**

Email: **support@innovateuk.ukri.org**

Website: **www.ukri.org/councils/innovate-uk**

Innovate UK Business Growth

Innovate UK Business Growth is Innovate UK's national business growth and scaling service. It is an integral part of the innovation agency's products and services portfolio.

The service is available to all established small to medium sized innovation-focused growth companies, including Innovate UK grant winners.

Innovate UK Business Growth accelerates its ambitious clients on their growth journeys with one-to-one support from over 450 Innovation and Growth Specialists and scaleup directors embedded in every UK region and nation. Their tailored, expert advice helps thousands of businesses sharpen their commercial strategies, realise the maximum value from their IP, raise game changing investment and take their businesses onto the global stage every year.

Contact

Phone: **+44 (0)300 123 3066**

Website: **www.iukbg.ukri.org**

Leading the Visit

Dr. Phil Packer
Innovation Lead
Innovate UK

Phil is the Innovation Lead for AMR and Vaccines at Innovate UK, and the Senior Responsible Officer for PACE (Pathways to Antimicrobial Efficacy).

Innovate UK have a One Health approach to AMR, funding SMEs and industry to develop new vaccines, antimicrobials and therapies for infectious disease in both humans and animals. In addition, capabilities and technologies are supported in Infection, Prevention and Control to reduce further spread of antimicrobial resistance in the Human Health, Environment and Agri-sectors.

Phil is responsible for developing and delivering funded calls, supporting workshops and strategy, including a £40M programme of work developing vaccines for diseases that have outbreak potential as part of the DHSC UK Vaccine Network programme.

Contact
Phone: **+44 (0)7789 944629**
Email: **phil.packer@iuk.ukri.org**

Sophie Mifsud
Europe Partnership Manager
Innovate UK

Sophie works in the Global Team at Innovate UK. Innovate UK's Global Team exists to support innovative businesses across the UK to achieve faster growth and scale by enabling their international engagement, helping to break down the barriers hindering businesses' ability to internationalise and put them at the forefront of international innovation opportunities. She is responsible for the relationship with several European countries including Switzerland.

Sophie has been part of the Global Team for three years and is also a member of the Network of European Innovation Agencies (Taftie), building relationships and sharing best practice across 28 European states and five International Partners.

Sophie has a background in stakeholder management, communications and partnership building in government and the third sector.

Contact
Phone: **+44 (0)7849 310405**
Email: **sophie.mifsud@iuk.ukri.org**

Leading the Visit

Bita Najafi
Project Manager
Innovate UK Business Growth

Bita joined Innovate UK Business Growth in 2021 and is supporting SMEs in achieving their international business objectives and to help them expand into new markets.

She holds a Master's Degree in Medical Genetics and an MA in Counselling and psychotherapy.

Bita has over 20 years of experience in the medical and healthcare sector and has successfully set up and grown businesses. She has also invested in a number of early stage MedTech companies. During her career she has worked in international markets and supported her clients to grow significantly.

Bita now leads on the delivery of Global Business Innovation Programmes for Innovate UK.

Contact
Phone: **+44 (0)7729 116379**
Email: **bita.najafi@iukbg.ukri.org**

Rocky Moore
Innovation & Growth Specialist
Innovate UK Business Growth

Rocky is an Innovation & Growth Specialist and has been supporting SME growth for many years. Before delivering the Innovate UK Business Growth service, he was a successful entrepreneur, enabling him to understand what business owners go through to achieve business growth.

One of Rocky's key attributes to supporting SMEs is his ability to connect and develop reciprocal relationships ensuring they link in with long term strategies.

He has particular experience in helping companies internationalise from delivering GBIPs with Germany and Switzerland across several sectors.

Contact
Phone: **+44 (0)7899 953653**
Email: **rocky.moore@iukbg.ukri.org**

Leading the Visit

Dr. Philipp Schneider

Science & Innovation Officer

Science & Innovation Network, British Embassy Berne

Philipp is part of the UK Science & Innovation Network and based at the British Embassy in Berne. He maintains the UK government's science and innovation interests in Switzerland and facilitates bilateral collaboration in research and innovation working closely with the Swiss government and S&I actors. Through his work, he supports the delivery of the UK Swiss Memorandum of Understanding on Collaboration in Research and Innovation. SIN Switzerland's sectoral priorities cover Life Sciences (incl. AMR), Energy & Cleantech, Climate, Artificial Intelligence, Data, Space, and Quantum.

Previously, Philipp served as Principal Scientist at the Competence Unit High-Performance Vision Systems at the Austrian Institute of Technology (2021-2024). Philipp is a Visiting Professor at the University of Southampton, UK, where he was Academic Director of the µ-VIS X-Ray Imaging Centre and Professor of Biomedical Imaging (2013-2023). Philipp is a physicist and medical physicist with a PhD in biomedical engineering from ETH Zurich (2007).

Contact
Phone: **+41 79 726 60 14**
Email: **philipp.schneider@fcdo.gov.uk**

Overview of Companies

Aetosense
Molly Haugen - CEO
Phone: +44 (0)7943 729973
Email: molly.haugen@aetosense.com
Website: www.aetosense.com

AGA Nanotech Ltd
Harsha Siani - CE0
Phone: +44 (0)7580 510210
Email: hs@aga.bio
Website: www.agananotech.com

Aisthesis Medical
Ioannis Gkouzionis - CEO
Phone: +44 (0)7801 360784
Email: igkouzionis@aisthesismed.com
Website: www.aisthesismed.com

Aridom Sanex
Anca Haralambie - Co-founder | Managing Director
Phone: +44 (0)7727 770744
Email: anca.haralambie@aridomsanex.co.uk
Website: https://aridomsanex.co.uk

Aseptuva
Eashan Saikia - Chief Technology Officer
Email: es@aseptuva.com
Website: www.aseptuva.com

Astratus Limited
Julie Hart - Chief Medical Officer
Phone: +44 (0)7590 585643
Email: julie.hart@astratus.co.uk
Website: www.astratus.co.uk

BioTryp Therapeutics Ltd
Ashraf Zarkan - CEO & Director
Phone: +44 (0)7909 463260
Email: ash@biotryp.com
Website: www.biotryp.com

DRUiD
David Howarth - CEO
Phone: +44 (0)7710 092997
Email: david.howarth@druid.health
Website: www.druid.health

LabReady
Philip-Michael Weiner - Co-Founder
Phone: +1 650 449 6334
Email: phil@labready.com
Website: www.labready.com

M&F Tech LTD
Xinqi Li - CTO
Phone: +44 (0)7950 333560
Email: xinqi.li@mf-ai.co.uk
Website: www.mf-ai.co.uk

MiDx Ltd
Shaun Robertson - CEO
Phone: +44 (0)7714 276746
Email: shaun.robertson@mi-dx.com
Website: www.mi-dx.com

mycoBiologics Limited
Fiona Rudkin - CEO
Email: fiona.rudkin@mycobiologics.com
Website: www.mycobiologics.com

Nextsense Ltd
Omar ElFata - Chief Business Development Officer
Phone: +20 100 1007430
Email: o.elfata@biovitae.it
Website: www.biovitae.it

Veirulence Ltd
Rory Triniman - CEO
Phone: +44 (0)7506 239272
Email: rtriniman@veirulence.com
Website: www.veirulence.com

Vesynta
Emily Heron - Business Development Officer
Phone: +44 (0)7580 903023
Email: emily.heron@vesynta.com
Website: www.vesynta.com

ZiO Health
Francesca Napoli - Director of Operations
Phone: +44 (0)7930 510253
Email: francesca.napoli@zio-health.com
Website: www.zio-health.com

Aetosense

Aetosense is developing technology that will be able to detect different types of particles, count them, and report that data into building management systems.

The technology developed will be able to both count and speciate particles, which currently cannot be done with any technology. However, Aetosense intends to create a technology that can address this exact need, all while being able to be mass produced and integrated into air handling systems, or as stand alone units in individual rooms. With this information, building owners and managers will be able to access this information and improve the understanding of how these particles spread around hospitals, care homes, schools, or offices.

Aetosense's technology strives to be accessible by all building operators, regardless of economic status. The knowledge gained from the technology's output data will help prevent microbial spread, in turn reducing resistance, specifically in vulnerable communities.

Visit objective

Aetosense seeks to understand the requirements for this type of technology, including cost, size, types and sizes of particles of interest, as well as gain potential connection for future partnerships.

Contact

Molly Haugen - CEO
Phone: **+44 (0)7943 729973**
Email: **molly.haugen@aetosense.com**
Website: **www.aetosense.com**
Industry: **Technology**

AGA Nanotech Ltd

AGA Nanotech: Transforming Infection Management with Battlestar™.

AGA Nanotech is revolutionising the fight against antimicrobial resistance (AMR) with its pioneering platform, Battlestar™. This disruptive technology overcomes longstanding barriers to safely and stably deliver oxidative biocides – peracetic acid (PAA) and hydrogen peroxide – directly at infection sites through a proprietary Poly(lactic-co-glycolic acid) (PLGA) delivery system. With its dual-action mechanism, Battlestar™ uniquely eradicates biofilms and drug-resistant pathogens while simultaneously fostering tissue regeneration – a breakthrough that sets it apart from traditional antimicrobials.

For the first time, healthcare can access a non-antibiotic solution that does not promote resistance and achieves sustained, controlled antimicrobial activity. Battlestar™ addresses critical clinical needs across wound care, osteomyelitis, urinary tract infections, and biofilm-associated tumours, offering unparalleled efficacy and safety in both acute and chronic infection management.

With a robust portfolio of granted international patents, Battlestar™ is positioned as a first-in-class, commercially scalable solution. AGA Nanotech is actively seeking licensing or acquisition partnerships with healthcare leaders to accelerate its global impact, ensuring this revolutionary technology reaches patients and healthcare systems worldwide.

AGA nanotech

Contact

Harsha Siani - CE0
Phone: **+44 (0)7580 510210**
Email: **hs@aga.bio**
Website: **www.agananotech.com**
Industry: **MedTech**

Visit objective

To secure strategic partnerships, explore licensing opportunities, and gain market insights to accelerate the development and future commercialisation of Battlestar™, advancing AGA Nanotech's mission to 'Preserve Antibiotics, Protect Patients, and Prevent Resistance'.

Aisthesis Medical

Aisthesis Medical: Transforming Sepsis Care with Predictive AI.

Aisthesis Medical is a pioneering digital health company specialising in AI-powered solutions for early detection and intervention in life-threatening conditions like sepsis. At the core of its innovation is VIOSync™, an advanced Clinical Decision Support Software (CDSS) that leverages explainable artificial intelligence to analyse multimodal patient data, enabling clinicians to predict sepsis up to 48 hours before clinical symptoms appear.

VIOSync™ integrates seamlessly with hospital Electronic Health Records (EHRs), providing real-time insights to improve patient outcomes, reduce ICU admissions, and optimise hospital workflows. The software's explainable AI capabilities ensure transparency, enhancing clinician trust and facilitating adoption into existing care pathways.

Committed to sustainability and global collaboration, Aisthesis Medical aims to contribute to the fight against antimicrobial resistance (AMR) through early sepsis detection and precision-based interventions. By joining the Innovate UK GBIP AMR delegation to Switzerland for the 9th AMR Conference, Aisthesis seeks to engage with key organisations such as Innosuisse, the Swiss Biotech Association, and Swissnex, fostering partnerships that will accelerate the development, clinical validation, and international adoption of its VIOSync™ technology. Through these collaborations, the company aspires to enhance patient care while addressing global healthcare challenges linked to AMR.

Visit objective

To establish strategic partnerships with Swiss healthcare innovators, research institutions, and biotech companies to accelerate the clinical validation, regulatory approval, and global adoption of VIOSync™.

Contact

Ioannis Gkouzionis - CEO
Phone: **+44 (0)7801 360784**
Email: **igkouzionis@aisthesismed.com**
Website: **www.aisthesismed.com**
Industry: **MedTech**

Aridom Sanex

Aridom Sanex delivers state-of-the-art, eco-friendly decontamination solutions for air, surfaces, objects, and water, addressing contamination control and combating antimicrobial resistance (AMR) across critical industries. Leveraging advanced hypochlorous acid (HOCl) technology, the company provides highly effective, non-toxic solutions to prevent contamination, combat AMR, and ensure superior hygiene standards in healthcare, cleanrooms, agriculture, and environmental management.

At the heart of Aridom Sanex's innovation are state-of-the-art systems, such as dry fogging technology and on-site HOCl generation, enabling seamless, scalable decontamination that is residue-free and safe for humans, animals, and the environment.

With a strong commitment to sustainability, Aridom Sanex supports high-level contamination control while minimising environmental impact. Its solutions align with Switzerland's focus on advancing AMR strategies by delivering robust, off-grid technology capable of providing comprehensive hygiene for critical environments.

Visit objective

Aridom Sanex aims to partner with Swiss companies to deliver sustainable decontamination, combat AMR, foster R&D, and align with Switzerland's innovation and sustainability goals.

Contact

Anca Haralambie - Co-founder | Managing Director
Phone: **+44 (0)7727 770744**
Email: **anca.haralambie@aridomsanex.co.uk**
Website: **www.aridomsanex.co.uk**
Industry: **Biotechnology and Sustainable Contamination Control**

Aseptuva

Aseptuva is a MedTech startup with the vision to combat hospital acquired infections (HAI) arising from contamination of catheter-entry sites in patients who are admitted to ICUs or general wards for several days.

They are developing an in-situ Far-UVC disinfection system, which is compact enough to fit underneath wound dressings, and continuously disinfect the skin perforation site in a safe and hands-free manner. This will alleviate significant burden on the nursing staff by eliminating the need for complicated wound cleansing procedures, reduce discomfort experienced by patients, and importantly, it has the potential to lower the use of antibiotics that are otherwise administered as a part of current infection-prevention and control (IPC) procedures.

Aseptuva has been awarded funding support by Innovate UK and by NIHR's i4i programme, and their team is closely working with several NHS trust hospitals in the UK to bring their products closer to adoption.

aseptUVa

Contact

Eashan Saikia - Chief Technology Officer
Email: **es@aseptuva.com**
Website: **www.aseptuva.com**
Industry: **MedTech**

Visit objective

Aseptuva wishes to participate in the GBIP's AMR programme, to explore the Swiss healthcare ecosystem, meet with Key Opinion Leaders in critical care, and engage with future customers.

Astratus Limited

Astratus Limited is a recent University of Reading spin out company modernising traditional microbiology laboratory methods.

The Astratus rapid, accurate, high throughput laboratory platform significantly reduces time to result and is less labour intensive. When managing urinary tract infection (UTI), the Astratus technology enables the right treatment to be prescribed to the right patient playing a vital role in antimicrobial stewardship and helping tackle antimicrobial resistance.

Astratus is a One Health company serving human, veterinary and research markets offering a novel microcapillary "dip and test" cassette and instrument reader platform for antimicrobial susceptibility testing (AST) either direct from urine or from bacterial isolates. At the core of the innovation are two existing laboratory methods combined with the unique patented properties of the microcapillary film and time lapse imaging delivering rapid AST for up to 13 antibiotics from one urine sample.

The rapid AST platform provides digital results direct from urine in <6 hours, instead of several days, performs identically to clinical reference standard methodology and can be easily scaled to increase throughput. As well as providing a platform for rapid AST, the Astratus technology can be used by researchers and companies developing new antimicrobials, and investigating biofilms and novel therapies such as phage therapies.

Astratus

Contact

Julie Hart - Chief Medical Officer
Phone: **+44 (0)7590 585643**
Email: **julie.hart@astratus.co.uk**
Website: **www.astratus.co.uk**
Industry: **Microbiology laboratory equipment manufacturer**

Visit objective

Astratus is looking to build R&D/innovation collaborations and partnerships with life sciences/biotech companies and academic/clinical institutions with an interest in One Health, AMR & novel antimicrobial therapies.

BioTryp Therapeutics Ltd

BioTryp Therapeutics is developing novel antibiofilm oral therapies for patients with bacterial infections.

Biofilms are communities of bacteria surrounded by a matrix protecting against antibiotics and the body's own defences. Biofilms occur widely in bacterial infections (e.g. urinary tract infections (UTIs), wound infections & respiratory infections) leading to treatment failure and complications.

BioTryp's 1st clinical application is UTIs, which are the most common bacterial infections affecting 400 million people per year worldwide (50% of women and 10% of men in their lifetime) and the treatment market was estimated at $9.89 billion. In UTIs, biofilms are associated with high rate of treatment failure, recurrent UTIs, and catheter-associated UTIs. There are currently no antibiofilm oral therapies for UTIs. Treatment relies exclusively on antibiotics, which struggle to clear biofilms leading to repeated use and increased resistance.

BioTryp's technology represents a game-changer in treatment of bacterial infections by inhibiting biofilm formation and forcing bacteria to stay apart thus increasing susceptibility to the immune cells and antibiotics. The primary application of BioTryp's technology will be as an add-on oral therapy prescribed along with existing frontline antibiotics to enhance treatment outcome and reduce failure, thereby reduce hospitalisation and provide significant benefits to patients and healthcare systems.

Visit objective

Through this programme, BioTryp aims to increase its visibility in the Swiss AMR network, establish potential partnerships and collaborations with Swiss programmes, and explore joint development interest from Swiss companies.

Contact

Ashraf Zarkan - CEO & Director
Phone: **+44 (0)7909 463260**
Email: **ash@biotryp.com**
Website: **www.biotryp.com**
Industry: **Therapeutics, Pharma**

DRUiD

DRUiD is a healthcare diagnostics company revolutionizing the fight against antimicrobial resistance (AMR) and infections through cutting-edge, scalable solutions.

Grounded in the One Health framework, DRUiD tackles the interconnected challenges of human, animal, and environmental health, recognizing that AMR requires a comprehensive, global approach.

At the heart of their innovation is Vita-Dx, a rapid, non-invasive diagnostic solution for UTI and AMR detection. By delivering real-time results, Vita-Dx empowers clinicians to make informed decisions, reducing unnecessary antibiotic use and advancing global AMR stewardship. Built for accessibility and scalability, our technology ensures its benefits extend across diverse healthcare systems worldwide.

Committed to sustainability, DRUiD seamlessly integrates AMR prevention with minimizing societal and environmental impacts. Through strategic partnerships and collaborations, they are driving impactful, forward-thinking solutions to strengthen and safeguard global health systems for generations to come.

Visit objective

To showcase DRUiD's innovative diagnostics, foster partnerships, and explore collaborative opportunities to advance AMR solutions and expand their global reach.

Contact

David Howarth - CEO
Phone: **+44 (0)7710 092997**
Email: **david.howarth@druid.health**
Website: **www.druid.health**
Industry: **Medical Devices**

LabReady

LabReady has developed a one-button, quantitative PCR (qPCR-AI) diagnostic platform, designed to provide fast, accurate results for five infections within minutes.

Unlike traditional PCR systems, which require refrigeration, dedicated lab space, and specialized handling, MyLabReady is pocket-sized and fully self-contained – eliminating the need for on-site refrigeration or sample preparation. This breakthrough makes gold-standard multi-target accessible to clinics, pharmacies, ERs, care homes, and remote military locations where PCR hasn't been feasible before. Its patented design avoids the dilution steps common in other PCR systems, achieving a 2700% increase in sensitivity over market leaders.

Meanwhile, onboard AI mimics technician oversight for quality control, allowing simultaneous testing for viruses and bacteria in a single cartridge, without having trained lab personnel in each clinic location.

With a $5 per-test cost, MyLabReady supports AMR management by enabling affordable, rapid, targeted diagnoses, reducing unnecessary antibiotic courses due to misdiagnosis. For patients with urinary tract infection (UTI-like) symptoms, MyLabReady can mean the difference between an immediate accurate treatment or months of ineffective antibiotics – while averting severe outcomes like amputations or discovering months later that the diagnosis is actually bladder cancer.

LabReady®

Contact

Philip-Michael Weiner - Co-Founder
Phone: **+1 650 449 6334**
Email: **phil@labready.com**
Website: **www.labready.com**
Industry: **Life Sciences**

Visit objective

To secure strategic partnerships and business development opportunities in Switzerland, accelerating commercialization of our AMR-focused MyLabReady diagnostic platform and fostering UK, EU and USA market entry.

M&F Tech LTD

M&F Tech Ltd is developing an AI-powered platform to revolutionize phage therapy, a method that uses phages to treat bacterial infections. The platform leverages advanced protein language models, based on a unique proprietary database, to accelerate phage discovery for bacterial infections. This innovation significantly reduces the traditional phage selection process from 1 to 3 months to just a few minutes.

M&F Tech Ltd's solution addresses the critical issue of antibiotic resistance by offering a rapid, precise, and scalable method for phage selection. This increased efficiency not only improves treatment outcomes—leading to faster recoveries and fewer side effects—but also reduces healthcare costs by minimizing the time and resources required for phage selection, ultimately decreasing hospital stays and overall treatment expenses.

Moreover, M&F Tech Ltd supports a Phage as a Service (PaaS) model, providing services such as phage discovery, database access, and expert consultation. This makes the platform accessible to healthcare providers, researchers, and pharmaceutical companies, marking a significant leap forward in the fight against bacterial infections and the growing threat of antibiotic resistance.

M&F Tech

Contact

Xinqi Li - CTO
Phone: **+44 (0)7950 333560**
Email: **xinqi.li@mf-ai.co.uk**
Website: **www.mf-ai.co.uk**
Industry: **Biotech**

Visit objective

To refine product development roadmap, enhance market entry strategies, and optimize supply chain management.

MiDx Ltd

MiDx Ltd is a medical technology company developing microbial diagnostic point of care devices.

MiDx is using patented biomarkers that are produced by the bacterium *Pseudomonas aeruginosa* to develop and clinically validate a lateral flow point of care device. This will help address an urgent need in *P. aeruginosa* infections in patients with underlying chronic respiratory disease such as Cystic Fibrosis, COPD and non-CF bronchiectasis. This has a significant healthcare burden and contributes to significant morbidity and mortality in patients.

These biomarkers have been clinically validated to be detected in a range of biofluids, providing a simple rapid testing format to inform clinical care to meet the urgent need. The device not only determines the presence of *P. aeruginosa* but also generates data on the virulence and is semi-quantitative with a device reader. The device can use non-sputum samples, a key advantage post-CFTR modulator therapy.

Health economics modelling has indicated this will be a cost-effective device which will support good antimicrobial stewardship. The device can use non-sputum samples, a key advantage post-CFTR modulator therapy.

Visit objective

MiDx's objective from this programme is to develop new networks and contacts to develop new opportunities in Switzerland and the wider European market.

Contact

Shaun Robertson - CEO
Phone: **+44 (0)7714 276746**
Email: **shaun.robertson@mi-dx.com**
Website: **www.mi-dx.com**
Industry: **MedTech**

mycoBiologics Limited

mycoBiologics are developing patient-derived monoclonal antibody (mAb) therapies to address the unmet need for new mode of action antifungal and antibacterial drugs, which are safe and effective at treating drug-resistant infections.

mycoBiologics' first mAb therapy, mB119, targets invasive Candida infections. Patients at high risk include those in intensive care units and those on immunosuppressant medications. mB119 is distinct from anything on the market or in clinical development. It does not interfere with other medications and patients may need only one or two doses of treatment over 7-14 days. This could shorten hospital stays and reduce healthcare costs. mB119 was derived from the immune response of a recovered patient thus it has distinct advantages over other similar approaches in preclinical development because it is more relevant to human markers of infection and is less likely to cause safety concerns in patients.

mycoBiologics' second patient-derived mAb product will be for the treatment of pneumonia due to the bacterium Acinetobacter baumannii.

mycoBiologics

Contact

Fiona Rudkin - CEO
Email: **fiona.rudkin@mycobiologics.com**
Website: **www.mycobiologics.com**
Industry: **Biotech**

Visit objective

Expand network and visibility within the UK and broader AMR field, and connect with future partners.

Nextsense Ltd

Founded in 2015, Nextsense is a science-driven company pioneering the health benefits of visible light wavelengths, with a focus on Infection Prevention and Control (IPC).

At the forefront of the Life-Centric Lighting sector, Nextsense develops sustainable, microbicidal solutions that enhance well-being. In 2016, the company patented BIOVITAE, a UV-free LED lighting system proven (in peer-reviewed studies) to kill SARS-CoV-2 and control microbial loads across various environments.

BIOVITAE integrates into products like household appliances, trains, and cars, providing continuous sanitization without UV radiation or harmful chemicals. By combining visible light frequencies, it ensures safer indoor environments, addressing microbial infections and antimicrobial resistance (AMR).

Nextsense's vision is to lead IPC innovation by transforming cutting-edge technology into practical solutions. Its mission is to harmonize sustainability and health, aligning with the European Union's goals for green transition and sustainable development. BIOVITAE has the potential to revolutionize lighting and sanitation, setting a new standard for healthier, infection-free spaces.

BIOVITAE®

Visit objective

To explore partnerships, showcase BIOVITAE's innovative IPC technology, and advance collaborations to address antimicrobial resistance (AMR) through sustainable, microbicidal solutions in alignment with global healthcare goals.

Contact

Omar ElFata - Chief Business Development Officer
Phone: **+20 100 1007430**
Email: **o.elfata@biovitae.it**
Website: **www.biovitae.it**
Industry: **Healthcare / Wellness / Lighting**

Veirulence Ltd

Veirulence is developing an antibiotic-sparing therapy to prevent and treat *P. aeruginosa* infections. The small molecule technology has a first-in-class anti-swarming mechanism and Veirulence is seeking collaborative R&D and commercial opportunities to progress preclinical development.

Veirulence has data indicating a synergistic activity with several classes of antibiotics. Priority R&D collaborations with experts in *P. aeruginosa* animal models and drug formulation. Exploration of a partnership for investigative microbiology and pathophysiology of virulence factors and drug target validation are also of high interest.

Veirulence's commercial interests include understanding the changing reimbursement landscape and the impact on commercialisation for innovative AMR products, as well as potential non-human applications for AMR virulence factor targeting.

Visit objective

Understand different key stakeholder perspectives on virulence targeting product development and reimbursement, explore commercial and R&D partnership opportunities, and learn best practices and insights from another market.

Contact

Rory Triniman - CEO
Phone: **+44 (0)7506 239272**
Email: **rtriniman@veirulence.com**
Website: **www.veirulence.com**
Industry: **Biopharma**

Vesynta

Vesynta is a HealthTech company, ensuring health equity through data-guided precision dosing.

Their decision support software, DosoLogic, maximises therapeutic safety and efficacy, by serving as a clinician copilot, offering personalised dose recommendations in real-time.

Combining quantitative pharmacology, electronic record integrations and real-world evidence, Vesynta's platform aligns with "One Health" stewardship priorities, ensuring appropriate antibiotic usage that mitigates short-term adverse events, long-term risks of resistance and enhances treatment efficacy.

The platform stands apart from competitors due to its interpretability, accessibility and marketplace. DosoLogic commoditises pharmacology data and connects clinical users with the right dose model for their patient. This ensures higher quality datasets and models that users can trust in their clinical setting. Furthermore, their models are more inclusive, removing the need for costly drug monitoring tests making personalised dosing available for more patients.

Visit objective

Vesynta aims to better understand the Swiss healthcare landscape, identify collaborations to support platform expansion, and implement pilots to deliver patient benefit.

Contact

Emily Heron - Business Development Officer
Phone: **+44 (0)7580 903023**
Email: **emily.heron@vesynta.com**
Website: **www.vesynta.com**
Industry: **Health Tech**

ZiO Health

ZiO Health has developed an advanced point-of-care hand-held diagnostic device to address antimicrobial resistance (AMR) through precise therapeutic drug and biomarker monitoring.

The hand-held device provides real-time, quantitative measurements of free and total antibiotic levels and biomarkers, such as procalcitonin, from a few drops of blood. This enables optimized antibiotic dosing, maintaining therapeutic levels to avoid resistance and toxicity, while supporting timely discontinuation when infection markers fall.

The proprietary biosensor technology is versatile, reagent-less, and calibration-free, capable of rapid analysis across fluids (blood, urine, saliva), leading to additional applications.

In collaboration with a US-based hospital, they are advancing antibiotic susceptibility testing with the use of phage monitoring, where their device analyzes antibiotic susceptibility within minutes, providing a powerful AMR solution. Future continuous monitoring capabilities will enhance real-time insights into drug efficacy, enabling more responsive interventions and supporting AMR prevention on a global scale.

ZIOHealth

Contact

Francesca Napoli - Director of Operations
Phone: **+44 (0)7930 510253**
Email: **francesca.napoli@zio-health.com**
Website: **www.zio-health.com**
Industry: **Medtech/Biotech**

Visit objective

ZiO Health is interested in collaborating with strategics and research institutions specializing in biosensors and in-vitro diagnostics (e.g., blood testing) for applications in AMR, biomarker & medication monitoring.

Innovate UK

Disclaimer

Whereas every effort has been made to ensure that the information in this document is accurate, Innovate UK (https://www.ukri.org/councils/innovate-uk/) does not accept liability for any errors, omissions or misleading statements, and no warranty is given, or responsibility accepted as to the standing of any individual, firm, company, or another organisation mentioned.

Any enquiries regarding this publication should be sent to contact@iukbg.ukri.org

Published in January 2025 by Innovate UK.